| [1] |
中华人民共和国国家卫生和计划生育委员会,中华人民共和国国家发展和改革委员会,中华人民共和国教育部,等.《中国癌症防治三年行动计划(2015-2017 年)》制订[J]. 中国肿瘤临床与康复,2016,23(2):177.
|
| [2] |
Ward EM,DeSantis CE,Lin CC, et al. Cancer statistics:breast cancer in situ[J]. CA Cancer J Clin,2015,65(6):481-495.
|
| [3] |
Jen J,Wu L,Sidransky D. An overview on the isolation and analysis of circulating tumor DNA in plasma and serum[J]. Ann N Y Acad Sci,2000,906:8-12.
|
| [4] |
Perkins G, Yap TA, Pope L, et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers[J]. PLoS One,2012,7(11): e47020.
|
| [5] |
Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing [J].Sci Transl Med,2012,4(162):162ra154.
|
| [6] |
World Health Organization.Breast cancer: prevention and control[EB/OL]. [ 2016-04-02 ]. http:/ /www. who. int/cancer/detection/breastcancer/en/index3.html.
|
| [7] |
Warton K, Mahon KL, Samimi G. Methylated circulating tumor DNA in blood: power in cancer prognosis and response[J]. Endocr Relat Cancer,2016,23(3):R157-171.
|
| [8] |
Saliou A,Bidard FC,Lantz O,et al. Circulating tumor DNA for triplenegative breast cancer diagnosis and treatment decisions[J]. Expert Rev Mol Diagn,2016,16(1):39-50.
|
| [9] |
Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers[J]. Nature,2012,486(7404):537-540.
|
| [10] |
Bettegowda C, Sausen M, Leary RJ,et al. Detection of circulating tumor DNA in early-and late-stage human malignancies[J]. Sci Transl Med,2014,6(224):224ra24.
|
| [11] |
Forte VA, Barrak DK, Elhodaky M, et al. The potential for liquid biopsies in the precision medical treatment of breast cancer[J]. Cancer Biol Med,2016,13(1):19-40.
|
| [12] |
Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med, 2013,368(13):1199-1209.
|
| [13] |
Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage[J].Nat Med,2014,20(5):552-554.
|
| [14] |
Bratman SV, Newman AM, Alizadeh AA, et al. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq[J]. Expert Rev Mol Diagn,2015,15(6):715-719.
|
| [15] |
Newman AM, Lovejoy AF,Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA[J]. Nat Biotechnol,2016,34(5):547-555.
|
| [16] |
Schwaederle M, Husain H, Fanta PT, et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood)circulating tumor cell DNA assay[J]. Oncotarget, 2016,7 (9):9707-9717.
|
| [17] |
Lanman RB, Mortimer SA, Zill OA, et al. Analytical and clinical validation of a digital sequencing panel for quantitative,highly accurate evaluation of cell-free circulating tumor DNA[J]. PLoS One, 2015,10(10):e0140712.
|
| [18] |
Murtaza M, Dawson SJ, Pogrebniak K, et al. Multifocal clonal evolution characterized using circulating tumor DNA in a case of metastatic breast cancer[J]. Nat Commun,2015,6:8760.
|
| [19] |
Diehl F,Schmidt K,Choti MA,et al. Circulating mutant DNA to assess tumor dynamics[J]. Nat Med,2008,14(9):985-990.
|
| [20] |
李京华,徐波,李红艳,等. 循环肿瘤DNA 定量方法的建立及其临床应用的初步研究[J].中华老年医学杂志,2010,29(1):38-41.
|
| [21] |
Olsson E,Winter C, George A, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease[J]. EMBO Mol Med,2015,7(8):1034-1047.
|
| [22] |
Haber DA,Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA[J]. Cancer Discov, 2014,4(6):650-661.
|
| [23] |
Maass N, Schütz F, Fasching PA, et al. Breast cancer update 2014 -focus on the patient and the tumour[J]. Geburtshilfe Frauenheilkd,2015,75(2):170-182.
|
| [24] |
Pereira E, Camacho-Vanegas O, Anand S, et al. Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers[J]. PLoS One, 2015,10(12):e0145754.
|
| [25] |
Schiavon G, Hrebien S, Garcia-Murillas I, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer [J]. Sci Transl Med,2015,7(313):313ra182.
|
| [26] |
Fasching PA,Brucker SY,Fehm TN, et al. Biomarkers in patients with metastatic breast cancer and the PRAEGNANT study network[J].Geburtshilfe Frauenheilkd,2015,75(1):41-50.
|
| [27] |
Sato KA, Hachiya T, Iwaya T,et al. Individualized mutation detection in circulating tumor DNA for monitoring colorectal tumor burden using a cancer- associated gene sequencing panel[J].PLoS One,2016,11(1):e0146275.
|
| [28] |
Huang Z, Gu B. Circulating tumor DNA: a resuscitative gold mine?[J]. Ann Transl Med,2015,3(17):253.
|
| [29] |
Stern HM. Improving treatment of HER-2-positive cancers:opportunities and challenges[J]. Sci Transl Med, 2012, 4(127):127rv2.
|